- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05351892
A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants
A Combined Single- and Multiple-dose, Open-label, Randomized, 2 x 2 Crossover Study to Investigate the Relative Bioavailability, the Safety and the Tolerability of Elinzanetant (BAY 3427080) in Healthy Female and Male Participants
Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.
The study treatment, elinzanetant, is under development to treat symptoms caused by hormonal changes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.
Participants of this study will be healthy and will have no benefit from administration of elinzanetant. This study, however, will provide information on how to use elinzanetant in people with vasomotor symptoms.
In previous studies, capsules containing smaller amounts of elinzanetant have been used. To reach the daily dose intended for treatment, 3 of these capsules had to be taken once a day. To reduce the pill burden and make it easier for patients to stick to the treatment, capsules with a higher amount of elinzanetant have been developed.
The main purpose of this study is to learn how much of the study treatment elinzanetant gets into the participants' blood when the same dose is taken as new capsule formulation compared to the old capsule formulation.
To answer this question, the researchers will compare:
- The (average) total level of elinzanetant in the blood (also called AUC)
- The (average) highest level of elinzanetant in the blood (also called Cmax) between both capsule formulations after taking one dose of each.
In addition, the researchers want to compare how much of the new and old elinzanetant formulations get into the blood after intake for 9 subsequent days.
All participants will take both formulations by mouth during the study. Each participant will be in the study for up to 12 weeks, including 10 treatment days for each formulation. Participants will stay in-house for 14 days per capsule formulation. In addition, one screening visit to the study site is planned.
During the study, the study doctor and their team will:
- Do physical examinations
- Take blood and urine samples
- Check vital signs
- Examine the participants' heart health using electrocardiogram (ECG)
- Ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant must be 18 to 45 years of age inclusive, at the time of signing the informed consent.
- Participants who are overtly healthy as determined by medical evaluation of the investigator, including medical history, physical examination, blood pressure, pulse rate, body temperature, laboratory tests, and cardiac monitoring
- Body weight of at least 50 kg and body mass index (BMI) within the range 18 to 30 kg/m^2 (inclusive)
- Male or female
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
- Diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention(s) will not be normal
- Known or suspected allergy or hypersensitivity to elinzanetant or any of their excipients
- Any history of or ongoing endocrine disease
- Any known impairment of testosterone synthesis and metabolism
- Poor venous access
- History of alcohol or drug abuse
- Regular use of prescription drugs, over-the-counter drugs, supplements (e.g. carnitine products, anabolics, high dose vitamins) or herbal products within 2 weeks or 5 half-lives (whichever longer) prior to the first study intervention administration
- Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them within 4 weeks prior to the first study intervention administration, e.g. any investigational drug, any CYP3A4 inducers including St John's Wort, any proton pump inhibitors, or any other drug known to induce liver enzymes (e.g. dexamethasone, barbiturates), and 2 weeks for any drug known to inhibit liver enzymes (e.g. itraconazole, macrolides) as well as grapefruit.
- Clinically relevant findings in the Electrocardiogram (ECG), such as second or third degree AV block, prolongation of ECG parameters (QTcF > 450 msec, QRS > 120 msec)
- Clinically relevant deviations of the screened laboratory parameters from reference ranges at screening or Day -1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A-B
Participants will receive a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
|
Soft gel capsule, oral
|
Experimental: Treatment B-A
Participants will receive a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
|
Soft gel capsule, oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the concentration versus time curve from zero to infinity of elinzanetant after single dose administration (AUC)
Time Frame: 0 to 84 hours after first dose on Study Day 1
|
AUC from time 0 to the last data point greater than lower limit of quantification (LLOQ) (AUC[0-tlast]) will be used as a primary parameter, if AUC cannot be determined in all participants.
|
0 to 84 hours after first dose on Study Day 1
|
Maximum observed drug concentration of elinzanetant in plasma after single dose administration (Cmax)
Time Frame: 0 to 84 hours after first dose on Study Day 1
|
0 to 84 hours after first dose on Study Day 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration versus time curve from administration of last dose until 24 hours after last dose of multiple dosing (AUC[0-24]md)
Time Frame: 0 to 24 hours post-dose on Study Day 12/13
|
0 to 24 hours post-dose on Study Day 12/13
|
Maximum observed drug concentration of elinzanetant in plasma after multiple dose administration (Cmax,md)
Time Frame: 0 to 24 hours post-dose on Study Day 12/13
|
0 to 24 hours post-dose on Study Day 12/13
|
Observed drug concentration of elinzanetant in plasma prior to next dose administration (Ctrough)
Time Frame: 0 to 24 hours post-dose on Study Day 12/13
|
0 to 24 hours post-dose on Study Day 12/13
|
Number of participants with treatment-emergent adverse events (TEAEs)
Time Frame: After first administration of study intervention until follow up (Day 14 of Period 2)
|
After first administration of study intervention until follow up (Day 14 of Period 2)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22050
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hot Flashes
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoCompleted
-
AmgenCompleted
-
Alison Huang, MDNational Institute on Aging (NIA)Completed
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedTreatment of Menopausal Hot FlashesUnited States
-
Donesta BioscienceSynteractHCRCompleted
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)CompletedHot Flashes | Hot FlushesUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedFever, Sweats, and Hot FlashesUnited States
-
University of PennsylvaniaForest LaboratoriesCompleted
Clinical Trials on Elinzanetant (BAY3427080)
-
BayerCompletedVasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenGermany
-
BayerCompletedVasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenUnited States
-
BayerCompletedHot Flashes | Vasomotor Symptoms Associated With MenopauseUnited States, Switzerland, Canada, Poland, Italy, Germany, Portugal, Norway, Slovakia, Czechia
-
BayerCompletedHot Flashes | Vasomotor Symptoms Associated With MenopauseUnited States, Netherlands, Hungary, Italy, Czechia, Israel, Greece, Austria
-
BayerCompletedVasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenJapan
-
BayerCompletedHot Flashes | Vasomotor Symptoms Associated With MenopauseBelgium, United States, Poland, Spain, Bulgaria, Finland, Canada, Denmark, United Kingdom
-
BayerNerre Therapeutics Ltd.CompletedHot Flashes | Menopause | Night WakingUnited States, Canada, United Kingdom
-
BayerCompletedHot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenChina
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenCanada